Abstract-The dopamine D2 receptor (DRD2) and dopamine transporter (DAT) play a regulatory role in dopaminergic neurotransmission and thus play an important role in drug addiction. The prefrontal cortex (PFC), a critical part of the mesencephalic dopaminergic system, is thought to be involved in the development and maintenance of drug addiction. The addiction to ketamine is thought to induce behavioral effects primarily through actions on the central nervous system. However, the neural mechanism underlying the effects of ketamine addiction remains unclear. In this study, we investigate the involvement of PFC DRD2 and DAT in ketamine addiction effects after ketamine administration for 10 weeks in nonhuman primates. To this end, after administering ketamine to rhesus monkeys for 10 weeks, we assessed changes in body weight and behavior. Additionally, neuronal changes in the PFC were examined by hematoxylin and eosin (HE) staining; the DRD2 and DAT mRNA and protein expression levels in the PFC were determined by real-time PCR and Western blot analysis, respectively. After 10-week ketamine administration, the assessment of the manifestations of toxicity in rhesus monkeys revealed significant changes in body weight and behavior, decreased DRD2 and DAT mRNA and protein expression in the PFC, and histological abnormalities including neuronal eosinophilia, pyknosis and disorderly arrangement of neurons in the PFC. These results suggest that the reduced expression of DRD2 and DAT in PFC could be involved in the behavioral and the neurological changes induced by ketamine administration, which may play an important role in the molecular mechanisms of ketamine addiction.
INTRODUCTION
Drug addiction poses a serious threat to people's health and life (Volkow and Fowler, 2000; Volkow et al., 2007; Liu et al., 2016) . Ketamine, an anesthetic, has hallucinogenic effects that can lead to its abuse (Narendran et al., 2005; Wolff and Winstock, 2006) . Nonmedical use of ketamine began soon after its approval as an anesthetic in 1970, but it is only since the start of this century that its use as a recreational drug became popular and its abuse is getting more and more serious worldwide, severely threatening human health (Shahani et al., 2007; Poon et al., 2010; Wang et al., 2013; Fan et al., 2015) . Ketamine is a noncompetitive N-methyl-Daspartate (NMDA) receptor antagonist. It can block the transmission of pain impulses, excite the limbic system and brainstem neurons, and lead to dissociative anesthesia and illusion with strong addiction (Lim, 2003; Kurdi et al., 2014) . After taking ketamine, there will be depersonalization, derealization, dreams and hallucinations (Giannini et al., 2000) . This experience is very similar to near-death experience (Zhang, 2016) and holds a strong attraction to it for users. Additionally, its intensity of action will gradually increase with the number of uses and doses. The abuse of ketamine will also cause damage to the nervous system (Hayashi et al., 2002; Yeung et al., 2010; Sun et al., 2011; Hansen et al., 2017) . However, the underlying neural mechanism remains largely unknown. The drug addiction process is closely related with the structural and functional changes in the dopaminergic system. Addictive drugs stimulate the reward response induced by dopamine and gradually cause addiction (Volkow et al., 2007) . The physiological effects of dopamine are mediated through a family of five closely related but functionally distinct dopamine receptors, as well as dopamine transporters.
Dopamine receptors belong to the G-protein coupled receptor family, which according to their interaction with adenylyl cyclase can be classified into D1 and D2 receptor types. The D1 receptor type includes D1 and D5 receptors, while the D2 receptor type includes D2, D3, and D4 receptors. Several studies have shown that D1, D2, D3, and D4 receptors have a certain relationship with addiction (Sokoloff et al., 2001; Vandenbergh et al., 2007; Batel et al., 2008; Le Foll et al., 2009 ). Among them, dopamine D2 receptor (DRD2) is widely expressed in the brain, especially in the prefrontal cortex (PFC) (Vincent et al., 1995) . DRD2 expression has been suggested to be closely related with drug addiction (Bressan and Crippa, 2005; Mehic-Basara et al., 2013; Clarke et al., 2014) . In addition, in the induction of heroin-seeking behavior, the triggering effect of heroin was found to be blocked by a DRD2 antagonist, indicating that DRD2 plays an important role in the relapse of drug addiction (Lu et al., 2001) . Dopamine transporter (DAT) is a membrane protein member of the solute carrier family 6 distributed throughout the brain in the dendrites and cell bodies of nigrostriatal, mesolimbic, and mesocortical dopaminergic neurons. It regulates the timing, extent, and range of dopamine receptor agonism, thereby regulating the dopaminergic signaling pathways and maintaining the steady state of dopamine in neurons. Impairment of DAT or loss of its function will disrupt dopamine homeostasis and lead to various neuropsychiatric disorders, such as Parkinson's disease, schizophrenia and drug addiction (Riddle et al., 2005) . Therefore, it is important to investigate the mechanisms of DRD2 and DAT in drug addiction.
The PFC is an important component of the reward circuit. It mainly receives afferent dopaminergic projection neurons directly from the ventral tegmental area of the midbrain and indirectly from nucleus accumbens dopaminergic projection neurons to the basal ganglia (ventral pallidum), which in turn, projects to the medial dorsal nucleus of the thalamus, which projects to the PFC. After the appropriate receptor stimulation, the amount of dopamine released is increased, thereby completing the reward effect. It has been reported that the PFC plays an important role in the dopamine reward circuit involved in drug addiction (Tzschentke and Schmidt, 2000) . In addition, as an important part of the cortical edge loop, the PFC participates in the development of drug addiction by increasing the response to the drug, craving for the drug, and drug-withdrawal period (Baddeley, 1996; Roberts et al., 2000) . Ketamine increases the release of dopamine in the PFC and may disrupt dopaminergic neurotransmission in the PFC and cognitive function associated with this region (Tzschentke and Schmidt, 2000) .
Rodents have been widely used as animal models of drug addiction (Peakman et al., 2003; Charbogne et al., 2014) , while nonhuman primates have rarely been used for this purpose. Nonhuman primates are highly similar to humans in terms of anatomy, physiology, genetics, metabolism, and motion. The use of nonhuman primates can generate experimental data close to those obtained with humans. The rhesus monkey exhibits brain structures that are highly homologous to the human brain, especially the PFC (Preuss, 1995) . Therefore, in order to model human clinical and biological features of ketamine abuse, rhesus monkeys were used in this study as an animal model of ketamine abuse for 10 weeks. In addition, the expression of DRD2 and DAT in the PFC of ketamine addicted monkeys was analyzed using a combination of ethological and molecular biotechnology methods at the whole tissue, cellular, and molecular levels. The neural molecular mechanism of ketamine addiction was examined in order to determine the theoretical basis for clinical prevention and treatment of this disease.
EXPERIMENTAL PROCEDURES

Ethical statement
Nonhuman primates (rhesus monkeys) were used in this study as an animal model. The animal study strictly followed the principles of reduction, replacement, and refinement (3R principles of animal use). Rhesus monkeys care and procedures were in accordance with the guidelines on the treatment of experimental animals (the National Science Foundation (2006), Publication No. 398, 2006-10-08 
Experimental animals
Eight healthy adult male rhesus monkeys were purchased from Guangzhou Xusheng Biological Technology Co., Ltd (Guangzhou, China). Each rhesus monkey had a Guangdong Province experimental animal quality certification. The monkeys had good nutrition, normal mental state, no neurological history, and no history of drug use. They were randomly divided into two groups: the ketamine addiction group (n=4) and the saline control group (n=4). There was no significant difference in the 
Ketamine addiction model
We established a ketamine addiction model in rhesus monkeys using a dose escalation method (Anderson et al., 2001; Xie et al., 2019 ) with a modeling period of 10 weeks. Ketamine injections were intramuscularly administered to the rhesus monkeys in the ketamine addiction group, starting at a minimum dose of 0.4 mg/kg/d (saline diluent). An intragluteal injection of ketamine was administered once a day (at 10:00 A.M.) for 3 consecutive days, and then halted for 1 day. The dose was then doubled in the second week and again in the third week, and subsequently maintained thereafter from the beginning of the fourth week to the end of the tenth week, as shown in Table  2 . The monkeys in the saline control group were injected with the same 0.9% dose and at the same time as the monkeys in the ketamine addiction group.
Behavioral observations
During the modeling period, the changes in the weight and behaviors of the animals in the two groups were assessed throughout the 10-week period. The body weight of all the rhesus monkeys was measured weekly. Three researchers with previous professional training independently performed behavioral observation of the rhesus monkeys. Addiction behaviors of rhesus monkeys, such as irritability, piloerection, runny nose, etc., were observed by using uniform behavioral scoring criteria (Xie et al., 2019) , recorded three times a day at 08:00 A.M., 02:00 P.M. and 08:00 P.M., and observations were performed at least every 2 h. When the scoring results of the three researchers showed obvious differences, they were either discussed or the animal was observed again to reach a consensus. Ultimately, the average value of the behavior scores of the rhesus monkeys that were recorded three times on the same day, was considered as the behavioral score of that day, according to the observation and measurement results from the three researchers. There were four different grades assigned (mild, moderate, severe, and extremely severe) according to the behavioral symptoms of the rhesus monkeys during addiction as shown in Table 3 .
Specimen extraction
All monkeys were euthanized by air embolism at approximately 24 h after modeling. After cutting the skull, according to the histology atlas of the rhesus monkey brain (Saleem, 2012) , the monkey brain was completely removed and the PFC was separated and dissected. Then, a part of the PFC specimen was stored at − 80°C and the remaining was suspended in a 4% paraformaldehyde solution for subsequent analysis. The specimens were fixed in 4% paraformaldehyde for 24 h and embedded in paraffin. Then, paraffin embedded tissue specimens were sliced in 4-μm-thick sagittal continuous sections. Adjacent sections were subjected to conventional hematoxylin and eosin (HE) staining and immunohistochemistry (IHC) staining. Extreme discomfort, lying on the side with the eyes closed, abnormal posture, vomiting, pale complexion, marked muscle spasm.
Extremely Severe
The level difference of extremely severe grade is 32 points; 4 points per symptom; Failure symptom is 20 points.
Failure symptom (no expression, difficulty breathing, severe dehydration).
The total score is calculated according to the formula: S = A+B; S = Total score of the symptoms of each rhesus monkey, where A = The level difference, and B = The total score for all symptoms in a day. If a symptom is repeated throughout the day, the symptom score should be reduced by 1 point.
HE staining
Serial 4-μm paraffin sections of the PFC tissue specimens were deparaffinized and stained with HE for microscopic examination. Histological analysis was performed in a blinded manner by an experienced pathologist using a light microscope equipped with a computer-assisted morphometric system (Olympus, Tokyo, Japan).
IHC staining
IHC staining was performed by the Streptavidin-Peroxidase (SP) method, and diaminobenzidin (DAB) was used as a substrate. The primary antibodies used were the rabbit anti-monkey DRD2 polyclonal antibody (1:1000; LifeSpan BioSciences, Seattle, WA, USA) and the rabbit antimonkey DAT polyclonal antibody (1:1000; LifeSpan BioSciences). The secondary antibody used was the goat antirabbit BioEasy BE0101 (Beijing Xijie Technology Co., Ltd., Beijing, China); the negative control involved replacing the primary antibody with 0.01 M PBS.
Quantitative real-time polymerase chain reaction (qRT-PCR)
The frozen PFC tissue specimens were suspended in Trizol reagent (Invitrogen, San Diego, USA) after homogenization by grinding. Total RNA was then extracted using the onestep method according to the Trizol kit instructions. The concentration and purity of the RNA samples were determined using a NanoDrop®ND-2000 (Thermo Fisher Scientific, Waltham, MA, USA). cDNA reverse transcription was performed using the PrimeScript™ RT reagent Kit with gDNA Eraser (TaKaRa, Tokyo, Japan). GAPDH was used as an internal reference gene. The primer sequences and the amplified fragment length are shown in Table 4 . The PCR conditions were set at 95°C for 30 s and 40 PCR cycles (95°C, 5 s; 60°C, 40 s (collecting fluorescence)). The relative value of the mRNA expression of the DRD2 and DAT genes was calculated by comparing the cycle thresholds (CTs) of the target gene with that of the house keeping gene (GAPDH) using the 2 −ΔΔct method.
Western blot analysis
The protein was extracted and analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). After separation by SDS-PAGE, the gel was removed, rinsed with distilled water, and target protein bands were transferred onto a polyvinylidene fluoride membrane with a constant 100-mA current. The membrane was then blocked with nonfat milk powder and incubated with rabbit antimonkey DRD2 (1:1000; LifeSpan BioSciences) and DAT primary antibody (1:1000; LifeSpan BioSciences) at 4°C overnight. The following day, membrane was incubated with the secondary antibody (horseradish peroxidase-linked goat anti-rabbit, 1:10,000; Beijing ZSGB Biotechnology Inc., Beijing, China) at room temperature for 1 h. Then, after the chemiluminescence reaction, the membrane was exposed to a film, which was developed and fixed. The film was then either scanned or photographed, and the optical densities of the target bands were analyzed.
Statistical methods
The data are expressed as the mean± standard deviation (SD). Statistical analyses were performed using SPSS 20.0 software (IBM Corp., Armonk, NY, USA).The effects of ketamine on the weight and behavioral were investigated using a repeated measures analysis of variance (ANOVA); the weight and behavioral scores of between-group comparison were analyzed using the two independent-samples t-test. The qRT-PCR analysis and Western blot analysis data of the two groups were analyzed using the two independent-samples t-test. P < 0.05 indicated statistical significance.
RESULTS
Change in the body weight of the rhesus monkeys
At the beginning of the study, there was no statistically significant difference in body weight between the monkeys in the ketamine addiction group and the control group. The weight of the rhesus monkey in the addiction group gradually decreased following ketamine administration; the change was especially obvious after the fourth week (t (6) = − 4.382, P < 0.05), whereas monkeys in the control group Fig. 1 . The rhesus monkeys in the ketamine addiction group experienced significant body weight loss, whereas monkeys in the control group gradually gained some weight. * P < 0.05, *** P < 0.001 vs. control group.
gained some weight. After the ketamine administration, the weight of the rhesus monkeys in the addiction group was significantly lower than that before the intervention (F (9,27) = 514.200, P < 0.001), and their weight was also statistically significantly different compared with that of monkeys in the control group (t (6) =− 43.834, P < 0.001) (Fig. 1 ).
Behavioral change in rhesus monkeys
At the start of the experiment, the behavioral differences between the monkeys in the ketamine addiction group and the control group were not statistically significant (t (6) = − 9.16, P = 0.395). During the course of the study, the behavioral scores of the monkeys in the ketamine addiction group gradually rose following ketamine administration, especially after the fifth week. The main symptoms that were increased involved stereotyped behaviors, such as attack actions, like persistent scrambling, jumping, screaming and biting. After the ketamine administration, the behavioral scores of the monkeys in the ketamine addiction group were significantly higher than those before ketamine administration (F (9,27) =380.234, P < 0.001), and were also significantly higher than those of the monkeys in the control group (t (6) = 56.654, P < 0.001). The behavioral changes of the monkeys in the normal control group did not significantly differ before and after the intervention (Fig. 2) .
Morphological and ultrastructural destruction of PFC neurons in monkeys administered ketamine
The light microscope image of an HE-stained section of the PFC of a monkey from the control group showed homogeneous, loosely distributed nerve cells with spherical nucleus in the center of a lightly stained abundant cytoplasm and a clear nucleolus (Fig. 3A) . In comparison, the image of an HE-stained section of the PFC of a monkey after 10-week ketamine administration revealed disorderly arrangement of neurons, irregularly shaped neurons with shrunken cell body, some of which exhibit pyknosis, neuronal eosinophilia and loss of nucleolus (Fig. 3B ).
Subcellular localization of DRD2 protein by IHC staining
DRD2 was expressed on the cell membrane of neurons in the PFC from monkeys of the addiction and control groups. A difference in staining intensity was observed between the two groups, indicating that DRD2 expression was reduced in the ketamine addition group neurons compared with that in the control group neurons (Fig. 4) .
Expression of DRD2 mRNA in PFC neurons
The qRT-PCR analysis of the expression of DRD2 mRNA in PFC neurons revealed significantly lower levels of DRD2 mRNA in the PFC neurons of the ketamine addiction group Fig. 2 . The behavior score of the rhesus monkeys in the addiction group was clearly higher after ketamine administration, while no obvious change was observed in the control group. *** P < 0.001 vs. control group. Fig. 3 . Light-microscope Images of HE-stained sections of the PFC of monkeys: (A) The section of the PFC tissue from a monkey in the control group shows homogeneous, loosely distributed neurons with spherical nucleus in the center of a lightly-stained abundant cytoplasm, and a clear nucleolus.
(B) The section of the PFC tissue from a monkey in the ketamine addiction group reveals disorderly arrangement of neurons and irregularly shaped neurons exhibiting pyknosis, neuronal eosinophilia and loss of nucleolus ( Figure 3B ).
than in those of the control group(t (6) =− 31.570,P < 0.001) (Fig. 5) .
Expression of DRD2 protein in PFC neurons
DRD2 protein expression in the PFC was significantly decreased in the addiction group compared with that in the control group (t (6) =− 7.511, P < 0.001) (Fig. 6 ).
Subcellular localization of DAT protein by IHC staining
DAT was expressed on the cell membrane of neurons in the PFC from monkeys of the addiction and control groups. A difference in staining intensity was detected between the two groups, indicating that DAT expression was decreased in the ketamine addition group neurons compared with that in the control group neurons (Fig. 7) .
Expression of DAT mRNA in PFC neurons
The qRT-PCR analysis of the expression of DAT mRNA in PFC neurons revealed significantly lower DAT mRNA levels in PFC neurons of the ketamine addiction group than in those of the control group (t (6) =− 10.766,P < 0.001) (Fig. 8) .
Expression of DAT protein in PFC neurons
DAT protein expression in PFC was significantly decreased in the addiction group compared with that in the control group (t (6) =− 11.891, P < 0.001) (Fig. 9 ).
DISCUSSION
Ketamine has become a popular recreational drug and its increasing abuse worldwide makes it a severe threat to public health. Due to its euphoric and hallucinogenic effects as well as its availability, it is easily abused. Besides euphoria and addictive behavior, ketamine has other the common characteristics of addictive drugs, such as neurotoxicity. The abuse of ketamine will result in functional and structural damage of neurons in the brain regions associated with addiction. However, the neural mechanism of ketamine addiction remains unclear. Many rodent models have been established to study the neural mechanisms of drug addiction, and most of them have focused on large-dose or acute toxicity. Research on the effects of ketamine addiction using nonhuman primates is lacking. In this study, the rhesus monkey was used as an animal model to study ketamine addiction. A combination of ethological and molecular biotechnology methods was used to investigate the neural molecular mechanism of the development of ketamine addiction, to provide a theoretical basis for its clinical prevention and treatment. During modeling, it was found that the magnitude of effect is highly influenced by the rate of drug administration. For example, prolongation of the administration time and increase of the dose led to reduced food intake and thus gradual weight loss in addiction group monkeys. Also, the effects were similar to those observed in humans who use this drug. For instance, it has been reported that ketamine can stimulate the gastrointestinal tract, inhibit the mobility of smooth muscle (Wang, 2009) , and lead to digestive disturbance (Poon et al., 2010) . Here, we found that the rhesus monkeys in the addiction group displayed increased stereotyped behavior and energy consumption, leading to further weight loss.
In this study, prolonging the intramuscular administration of ketamine and increasing its dose in the rhesus monkeys led to abnormal behavior with gradually increasing trends. The main symptoms were increased . qRT-PCR analysis of the expression of DRD2 mRNA in PFC neurons. The DRD2 mRNA levels in PFC neurons of the addiction group and control group monkeys. GAPDH was used as a loading control. The mRNA level data are expressed as the mean ± SD, represented by a histogram and bar, respectively. *** P < 0.001 vs. respective control group. stereotyped behaviors, such as attack actions, like persistent scrambling, jumping, screaming, and biting, which are similar to those observed in humans who abuse drugs for a long time (Homer et al., 2008) . Behavioral changes were especially obvious at the end of the 10-week administration period, after completion of the modeling. The main manifestations that were observed included persistent vertical exploration, and climbing. After a certain period of time, these behaviors gradually disappeared and the monkeys were tired, curled up, listless, and sleepy. In addition, they displayed a quick jump-and-attack action, even under the slightest stimulation. The toxic and side effects of ketamine are dosedependent (Newcomer et al., 1999) , and become more significant with the prolongation of the administration time, and increase of the dose. The main manifestations include mental and nervous system reactions, such as hallucination, dissociative state, screaming, excitement, dysphoria, and trembling, which are similar to those observed in schizophrenia patients. All of the above abnormalities are related to the increased addictive potential of low-dose ketamine (Trujillo et al., 2008) .
The histological analysis of PFC tissue sections from monkeys administered with ketamine for 10 weeks revealed irregularly shaped loosely distributed neurons with shrunken cell body, cytoplasmic shrinkage, pyknosis and neuronal eosinophilia. These observations indicated that after 10-week ketamine administration, the morphology of the PFC neurons changed. Ketamine can directly cause damage to neuronal cells, leading to neuronal apoptosis and neurodegeneration, thereby influencing the neurological functions of various brain regions Wai et al., 2013) .
The expression of DRD2 mRNA and protein in the PFC was reduced as a result of 10-week ketamine administration. The reduction of the number or sensitivity of DRD2 receptors induced by addictive drugs, such as ketamine, will increase dopamine levels and decrease the efficiency of the dopamine system. A potential reason for this is that ketamine can cause an increase in dopamine release in PFC (Tzschentke and Schmidt, 2000) , which, in turn, excites dopaminergic neurons, thus increasing the level of dopamine in the synaptic cleft. Dopamine acts through DRD2, to activate the dopaminergic pathway, resulting in a reward effect. While DRD2 is continuously stimulated by excessive dopamine, its sensitivity is gradually reduced, through downregulation of the expression of DRD2. The decrease in DRD2 levels gradually reduces the ability of addicts to receive rewards, thus pushing the addicts to continue to use addictive drugs in order to maintain the reward effect. The continued use of addictive drugs leads to further reduction of the DRD2 levels, slowly creating a vicious cycle of withdrawal-relapse, which explains why addiction is such a difficult disease to overcome.
DAT mRNA and protein expression in the PFC are reduced by 10-week ketamine administration. DAT regulates the dopamine signaling in the dopaminergic system, and contributes to the maintenance of dopamine homeostasis in dopaminergic neurons. Addictive drugs can impair dopamine homeostasis and lead to abnormal DAT levels (Sekine et al., 2003) . This study revealed that 10-week ketamine administration can decrease DAT expression in the PFC. Such reduced expression of DAT can result in the impairment of the mechanism for transporting dopamine from the synaptic cleft into the neuron, which in turn disrupts dopamine homeostasis and causes the accumulation of dopamine in the synaptic cleft to continuously activate the reward system (van der Stelt and Di Marzo, 2003; O'Doherty, 2004) . Accordingly, this finding suggests that ketamine can enhance the reward effect. The decrease in the DAT levels caused by abuse of addictive drugs leads to changes in the presynaptic membrane and postsynaptic membrane, resulting in decreased levels of dopamine in the cells and increased levels of dopamine between synapses (Jones et al., 1998) . This study also suggests that the abuse of ketamine can lead to a reduction in the distribution, number, and activity of DAT molecules on the cell membrane of neurons in the PFC, further indicating the impaired function of dopaminergic neurons.
Moreover, this study showed that ketamine can induce the release of dopamine in the PFC, which is involved in behavioral control (Frith and Dolan, 1996; Sakagami and Tsutsui, 1999) . Meanwhile, ketamine binds or blocks DAT (reducing DAT expression) to inhibit the reuptake of dopamine and maintain high levels of extracellular dopamine. Dopamine activates the dopaminergic system through DRD2 to generate rewarding effects, which in turn lead to the corresponding behavioral change. Once the test animals experience the reward effect, they will start to have drug-seeking behavior, and in humans, they will cause euphoria and drug abuse. This further illustrates the possibility that drugs which produce the reward effect are abused, and repeated use can lead to behavioral sensitization (Robinson and Berridge, 2000) . Since DRD2 is continuously stimulated by excessive dopamine, its sensitivity is gradually reduced, leading to hyporesponse of the DRD2 receptors. As a result, drug addicts must to continue using ketamine in order to achieve hallucinogenic effects by pathologically stimulating the reward pathway to release dopamine. We hypothesize that the corresponding behavioral changes are a progressive increase in drug-seeking behavior and uncontrollable impulsive behavior (Robinson and Berridge, 1993; Jentsch and Taylor, 1999) . Ketamine addiction can lead to a reduction in the distribution, number, and activity of DAT molecules on the cell membrane of neurons in the PFC, further indicating the impaired function of dopaminergic neurons. After administration of ketamine for 10 weeks, the downregulation of DRD2 and DAT in the PFC may result in the behavioral changes associated with ketamine addiction, which may be one of the important molecular mechanisms involved in ketamine addiction. This is one of the main reasons for the vicious circle of withdrawal-relapse in drug addicts who cannot completely withdraw from drugs.
CONCLUSIONS
We successfully established a ketamine addiction model in rhesus macaque monkeys. This study revealed that administration of ketamine for 10 weeks led to significant changes in both the body weight and behaviors of the rhesus monkeys, which may be closely related to the decreased in DRD2 and DAT expression in PFC. These findings suggest that DRD2 and DAT are involved in the physiological processes changes and pathological behaviors that result from ketamine addiction, which might be an important molecular mechanism underlying ketamine addiction. qRT-PCR analysis of the expression of DAT mRNA in PFC neurons. The DAT mRNA levels in PFC neurons of the of the addiction group and control group monkeys. GAPDH was used as a loading control. The mRNA level data are expressed as the mean ± SD, represented by a histogram and bar, respectively. *** P < 0.001 vs. respective control group. 
